Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18344208 | 0.82 | — | — | |
| SCHEMBL20296780 | 0.82 | HDAC6 (0.45) | HDAC6HCRTR1HCRTR2 | |
| SCHEMBL20296520 | 0.80 | MGLL (0.46) | HDAC6LMNATSHR | |
| SCHEMBL20296328 | 0.79 | RAB9A (0.52) | HDAC6LMNATSHR | |
| SCHEMBL20296507 | 0.78 | HDAC6 (0.48) | HDAC6LMNATSHRHCRTR1HCRTR2 | |
| SCHEMBL28821900 | 0.77 | HDAC6 (0.49) | HDAC6 | |
| SCHEMBL29363952 | 0.77 | MAPT (0.46) | LMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL20296686 | 0.76 | HDAC6 (0.44) | HDAC6HCRTR1HCRTR2 | |
| SCHEMBL20296248 | 0.76 | KDM4E (0.51) | HDAC6LMNATSHR | |
| SCHEMBL28821901 | 0.76 | HRH3 (0.48) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | ACACB 1215/4885HDAC6 303/4885LMNA 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.